Register for our free email digests:
Latest From Ethypharm SA
R&D-based big pharma groups in China with sufficient cash flow are increasing their strategic investments in overseas companies and products with an eye on entry to the global market, while start-ups continue to actively raise new funds from venture capitalists.
Dianbo Liu, chairman of the Hong Kong listed Luye Group, talks about the company’s ambitious plans to become a global top 100 pharmaceutical company through innovation, acquisitions and overseas expansion, and to broaden its activities well beyond selling medicines to meet changing patient needs and industry pressures.
French firm Ethypharm’s portfolio in CNS and pain management is apparently attracting interest from Chinese and other pharma groups in a potential strategic acquisition, with Luye Pharma and Mundipharma emerging as possible bidders given their interest in M&A as a route to business expansion.
A Hangzhou-based developer of traditional Chinese medicines (TCMs) has been given the green light by the U.S. Food and Drug Administration to conduct Phase III trials with an injectable TCM-based anticancer drug, which could become the first of its type to enter the U.S. market. The company is also seeking strategic partnerships with big pharmas to advance the trials and for future global development.
- Implantable Devices
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- BAROnova Inc.
- Senior Management
David S Thrower, Pres. & CEO
Kobi Iki, VP, R&D
- Contact Info
Phone: (805) 681-7000
281 Magnolia Ave., Ste. 300
Goleta, CA 93117
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.